Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Did anyone sanction the RS and if so why ?
I voted my 50000 shares no for the RS . The following three posts aided in my decision.
------------------------------------------------------------------
geocappy1 Wednesday, 08/31/16 10:53:17 AM
Re: CloakedProtector post# 271253
Post # of 272872
I will vote no. If I was sure they were only using authorization for extending nasdaq for 6 months and seeing what happened with other events then maybe. But of course they didn't give us that and I don't trust them
To me, going of the Nasdaq is not the death sentence you lay out and if they have what you say or they say then it won't matter. There is other funding out there (which they shouldn't need much if they deliver on Avids). It might be more expensive but not as detrimental as increasing PPS through RS and allowing shorts more room to bury us.
IMO we are idiots if we give the same BOD with the same lack of communication another run without exacting a price for their miscalculations. Paul Lytle at $700k is joke. The same BOD is also a joke. We have no other leverage but to try to stop the RS (sure no hope with folks like yourself accepting any and everything they do) without some type of fight.
I can only hope the Darts and limited institution support is against it. There should be some price to pay for the mistakes they have made(insistence on going it alone).
------------------------------------------------------------------
Wednesday, 09/07/16 10:01:56 AM
Re: bidrite post# 271700
Post #
271725 ( Threes )
of 272873 Go
I received my proxy today from TD.
Withheld BOD,
FOR E&Y,
AGAISNT reverse split, that was no brainier.
It's like going into surgery and the doctor asking with or without anesthesia and should I wipe off the scalable.
Unless you love pain and want to die it's pretty easy decision.
RS will kill shareholders 95% of the time stocks that RS return to the pre split SP.
So end of the day 100,000 shares at .40 will be 14,500 shares at .40. What a great deal that will be for shareholders.
We have 60 million in the bank . USE IT WISELY.
Against compensation, they should be cutting there salaries or taking zero dollars until they cut cost and turn a profit via AVID.
Get Adaptive Portfolio and We'll Waive our Advisory Fee until 2017
------------------------------------------------------------------
biopharm Member Level Sunday, 09/11/16 08:56:55 AM
Re: BioBS2012 post# 272265
Post # of 272874
BioBS2012, I agree and I think we should take it further... IF Peregrine makes a statement like this and foresees no need to raise funds for the next 12 months..... (playing devils advocate here..) that means there is certainly no emergency to get this stock over $1 VIA a RS so there should definately be an extension filed
I think it will happen naturally with pending PR's / Wolchok lab / Sunrise study data / Avid revenue..etc..etc
Quote:
"Although it is difficult to predict all of our future liquidity requirements, we believe that our cash and cash equivalents as of July 31, 2016 combined with
the additional proceeds raised subsequent to July 31, 2016 and through September 8, 2016, and the projected cash receipts from manufacturing services will be
sufficient to fund our operations through at least the next twelve months, which estimate assumes we raise no additional capital from the capital markets or other
potential sources."
As for the 1:7 even being brought up, I still have to say there is a party that owns 50%+ of the stock even though they may not be legally considered a group (but maybe that will change...) and would a group like this want to make a move on Peregrine or be willing to simply risk their shares being reduced .... => leaving the door wide open to give control to someone else that would be willing to come up with better terms for a M/A deal
------------------------------------------------------------------
I believe "Threes" post has hit the nail on the head. Threes I hope you do not mind if I repeat it again.
Threes Friday, 08/26/16 06:10:37 PM
Re: ku post# 270956
Post # of 271788
EVERYONE PLEASE VOTE NO, NO, NO, to the reverse split.
They will be able to carry us to profitability as they stated IF WE HOLD THERE FEET TO THE FIRE.
They have 60 million in cash and by there own words are 2 years from profitability.
Don't give me the crap about stilling owning the same percent of the company.
95% of the time all companies that reverse split go back to their pre split share price.
It is a loser.
PPHM is a OTC company.
They have not earned their wings to fly with the Nasdaq crowd.
There are plenty of OTC companies with good liquidity that trade multiples higher then PPHM.
There is no reason we could not trade OTC.
When we reach the requirements on our own due to merit we can go back to the Nasdaq.
This will also save the company two hundred thousand a year in compliance fees.
What we should be hearing is about drastic cost reductions in R & D and slashing BOD compensation.
Which can also go back up if/when they restore shareholder value.
Guns have now surpassed car accidents in cause of deaths in the USA.
------------------------------------------------------------------
How many people have to die before this tech gets into capable hands ! Do a deal now !!! 2NDSTR2THERT.
Entdoc this is what I found - see posts 226973 and 226976 - I assume they are still using these TNT products. You may also be interested in this post-78292- from FTM . It involves IHS-IL12 ( HUMANIZED TNT)
Pphm has licensed a TNT product -Vivatuxin-to a Chinese co.-Medipharm- it is being used to treat lung cancer in China . Because of the deal fashioned by our expert legal team we receive no revenues from this agreement. See post 226970 for more details.
Can anyone here make an argument why the " cost benefit ratio " for retail owners warrants voting for a reverse split ?
If I lived near Tustin I would apply for a permit to organize a picketing protest.
Waivers for what "stuff" ? Who knows what her intent was when she sabotaged the trial but the fact that she deliberately did it is another story. Is it common place for patients to sign a waiver even if there are entities running the trial that do not follow the protocols agree4d to at the time the waiver was signed ?
Why did she do that ?
It is hard to understand why the families involved did not sue JB and/or CSM.
25 years for me. Miss Golfdad's scientific input. I remember Lawsys and Wildhorses report on their trip to Tustin.
Around 1971 I read an article in long Islands Newsday that sparked my interest in the TNT platform. I understand why the switch to PS targeting but through the eyes of hindsight I am wondering if the TNT products should have been priority one. Stereotactic Therapies (Gama knife, Cyber knife, Proton beam tech) and radioactive seeds are still in use and from what I understand Cotara is a safer/better targeting agent.
People on this board have passed on waiting for our tech to be validated( OR invalidated ). GET MOVING TUSTIN.
Miss Freethemice's and Mojojojo's input.
Correction---"On The Shelf" posts are---226968 through 226971,226973,226976,226978,and226982.
Do we vote to authorize a reverse split ? I would rather go to the pink sheets then go through another reverse split- and have the share price in all probability fall back again.
Enough is enough I have supported this company for 25 yrs. It is time for them to appreciably increase the share price. They have had numerous products to leverage( See "On The Shelf" posts 226986-226971,226973,226976,226978,226982 ) . For those of you who do not know we have a product( Vivatuxin a form of Cotara and part of the TNT platform ) licensed and used for years by a Chinese co. ( Medipharm ) to treat lung cancer. The deal surrounding Vivatuxin was a debacle.
I was in my early 40's when I bought this stock now I'm near 70. Release something - anything - that will let me know if we are more than a manufacturing co.
Sorry for the rant.
This is the second time for this post--any answers ? TIA.
Did the families involved in our nscl phase 2 trial ever sue CSM ? INTENT INVOLVED ?
Did the families involved in our phase 2 lung cancer trial ever file a lawsuit against CSM ? Was "intent" involved ? If intent was proved would that impact PPHM ?
If I remember correctly when one of the arms of the tri body bavi antibody was armed its binding ability was diminished. I also recall that FTM had a possible solution for this - it was given in a reply to ENTDOC.
December 14, 2006Peregrine Pharmaceuticals and Biotecnol to Collaborate on Development of Immunocytokine Fusion Proteins for Cancer and Anti-Viral Indications
Builds on Peregrine's Recent Preclinical Studies Showing Anti-Phospholipid Immunocytokine Fusion Proteins Can Reduce Tumor Growth By Over 90%
TUSTIN, Calif. and OEIRAS, Portugal, Dec. 14 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted therapeutics for the treatment of cancer and hepatitis C virus (HCV) infection, and Biotecnol SA today announced a collaboration for the development of novel targeted immunocytokine agents for the treatment of cancer and other disease indications. The collaboration will apply technology from Peregrine's Vascular Targeting Agent (VTA) platform with Biotecnol's Tribody™ technology to engineer novel agents that fuse Peregrine's anti-phospholipid targeting agents to one or more cytokines in a Tribody format.
In September 2006 Peregrine reported new research showing that a novel fusion protein combining two proprietary Peregrine technologies--its anti- phospholipid and VTA platforms--with an immunostimulatory cytokine showed significant anti-tumor activity. The fusion protein reduced tumor growth in animal models by more than 90%, without showing evidence of the cytokine- induced toxicity that has limited the widespread therapeutic use of immunostimulatory cytokines such as interferon and interleukin. By fusing these cytokines with Peregrine's anti-phospholipid technology that directly targets tumor blood vessels, the combined fusion protein is expected to reduce both systemic toxicity and dosing frequency, while generating significant anti-tumor effects.
"This collaboration is an important step in developing clinical candidates that capitalize on the striking results we saw in tests of our fusion protein technology in animal cancer models," said Steven W. King, president and CEO of Peregrine. "Our anti-phospholipid platform is an ideal vehicle for targeting tumor blood vessels and delivering a cytokine payload with the goal of producing a very robust immune response while reducing systemic adverse events. We believe that Biotecnol's unique Tribody technology will contribute significantly to our ability to produce fusion protein drug candidates, and we therefore expect this collaboration to further broaden the potential of our proprietary VTA and anti-phospholipid platforms."
Biotecnol's Tribody technology uniquely allows engineering of multifunctional recombinant antibody derivatives, which utilize the natural in vivo heterodimerization of Fd fragments and light chains of a Fab fragment to form a scaffold upon which additional functions can be incorporated, such as additional binders, or cytokines, chemokines, growth factors, enzymes or protein toxins.
"This collaboration has great potential for designing superior immunocytokines based on the characteristics of our unique Tribody antibody engineering platform," said Pedro de Noronha Pissarra Ph.D., CEO of Biotecnol. "We believe that Peregrine has the proprietary technology and expertise to generate several antibody candidates for development as fusion proteins using our platform, with potential applications in oncology and infectious diseases. We are pleased to have the opportunity to contribute to the success of this project by providing a novel way to engineer these fusion protein candidates with unique properties and potentially safer profiles."
Under the collaboration, Biotecnol will engineer novel fusion proteins using one or more of Peregrine's anti-phospholipid antibodies or other targeting agents. The work will be performed as part of a research and development collaboration and is expected to result in a license agreement from Biotecnol to Peregrine for development and commercialization of the resulting agent or agents. Further details of the collaboration were not disclosed.
Peregrine's lead anti-phospholipid agent bavituximab is currently being studied in Phase l clinical trials in the U.S. for the treatment of solid cancers and chronic hepatitis C infection. In clinical data collected to date, bavituximab appears safe and well tolerated, and the company has reported promising signs of anti-viral activity in a Phase I HCV trial. Patient enrollment in a Phase Ib HCV trial has been completed, and a Phase lb solid cancer trial combining bavituximab and commonly-used chemotherapy regimens is now underway in India.
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing five separate clinical trials in cancer and HCV infection in the U.S. and India with its lead product candidates bavituximab and Cotara®. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.
About Biotecnol SA
Biotecnol SA is a biotechnology company focused on the development of biopharmaceutical products and has a special focus on the development of antibody-based therapeutics to treat life-threatening diseases such as cancer. Biotecnol has three types of proprietary antibody formats in development against various cancer targets. These formats are Tribodies™, Compact Antibodies and Armed Antibodies. Biotecnol is committed in building value by developing a diverse pipeline of antibody products to address unmet healthcare needs. Biotecnol applies its antibody technologies, product development and manufacturing experience to generate, support and potentially license out human antibody products. Biotecnol SA has a presence in the USA and carries out its product development activities via its fully owned subsidiary Biotecnol Inc. Through its facility in Portugal, Biotecnol leverages its business income by establishing in-house partner-led or collaborative programs, which provide Biotecnol a strong client-based activity and an established track record. Biotecnol uses its proprietary expression technology, cell line development capabilities, upstream and downstream processing, analytics and QC experience for delivering GMP/GLP compliant processes for biomanufacturing.
Safe Harbor Statement:
Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the results of clinical trials involving the fusion protein will not correlate to the results evidenced in the preclinical trials and the risk that the combined fusion protein to be developed in collaboration with Biotecnol will not reduce systemic toxicity and/or dosing frequency, nor generate statistically significant anti-tumor effects. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in our SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2006, and the quarterly report on Form 10-Q for the quarter ended October 31, 2006. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
Contacts:
Peregrine Pharmaceuticals Biotecnol SA GendeLLindheim BioCom Partners Dr. Pedro de Noronha Pissarra
Investors Media Chief Executive Officer info@peregrineinc.com Barbara Lindheim www.biotecnol.com (800) 987-8256 (212) 918-4650 +351-21-422-0520
SOURCE Peregrine Pharmaceuticals, Inc. 12/14/2006
Close window | Back to top
delicious Digg Facebook LinkedIn TwitterCopyright 2016 Peregrine Pharmaceuticals, Inc.
CP wasn't the DMC testing bloodwork all along and if so woudn't they be aware of any anomalies ?
Sunstar if you believe that the KM curves eventually would have shown the separation we hoped for why did PPHM stop the trial after the first look in ?
Opps forgot the question mark. Anyone have any thoughts on post 258274-tia.
I am going to assume that dr. Garnick will take longer than 3-16-16 to analyze the Sunrise phase 3 data. Unless a deal is already in the works wouldn't that make it likely that the poison pill will be renewed and therefore make it less likely that a deal will be forthcoming in the near term.
Wasn't the DMC testing blood samples all along and if so wouldn't they know if there were dosing mistakes ?
Vanessapu raised the possibility that we could run into trouble if a big pharma decided to present legal challenges to ultimately thwart our solvency. I would hope to hear more comments about this especially from our boards legal minds(North-Bungler). If as some believe the C.A. is impingeing on our ability to negotiate a deal/buyout then a legal attack by a big pharma to delay/deny the launch of Bavi becomes a possibility and we all know big pharma will do just about anything( sabotage )to protect themselves.
Would aligning ourselves with a big pharma now with a reduced value point be worth the potential protection ?
Are there some legal preventatives that could be done that would bolster our patten protections ?
I feel relatively secure that bavi works what concerns me is another sabotage attempt. Anyone know the name of the company overseeing our lung cancer trial? Their track record? Anyone care to speculate as to what if any added precautions PPHM and/or this company have taken to insure the integrity of the trial?
Thanks for the reply -just trying to get a simplistic handle on how bavi science works.
And why do we want Docetaxel to ellicit PS ?
I got this from post 152368-Dr.Brekken's words-
" These are ( MDSC'S )-I have to describe them as teenagers. These are cells that have not developed into their final form...They are unproductive in a lot of ways.So MDSC'S are present in tumors and they have a phenotype that drives immunosupression. However because these are teenagers, you can educate( them ).You can drive them towards a productive endpoint...However, there are ways in which we can educate these MDSC'S to differentiate into cells that are productive with respect to generating an immune response."
I do not understand why reducing MDSC'S is a good thing. It is my understanding that when MDSC'S are attached to bavi which in turn are attached to PS that this coupling enables the MDSC'S to foster an M1 state. One of the reasons Docetaxel is used with bavi is to ellicit PS. Why illicit PS unless there is a way to use it to produce a positive result ?
Robert if I remember correctly you were around for the whole China debacle. The anticipation for the sale and manufacturing of Vivatuxin rivaled our present hopes for Bavi.Hard to believe we own 500000 shares of a company ( Medifarm ) that is currently treating patients in China and they are worth ?
By the way we had to give Dr. Epstien $400000 to boot.
2ndstr2thert
Monday, 07/20/15 03:17:37 PM
post # of 229203
ON THE SHELF 2
For those who do not know PPHM owns shares in a Chinese company
that is and has been treating patients in China with one of our TNT products ( VIVATUXIN - TNT 3 AND I131 )and LYM 1.
Anyone have any idea how much these shares are currently worth in USA dollars ?
Peregrine Pharmaceuticals, Inc. (the “Company”) entered into a Settlement Agreement and Mutual General Release dated June 4, 2009 (the “Settlement Agreement”) with Cancer Therapeutics Laboratories (“CTL”), Alan Epstein, M.D. (“Dr. Epstein”), Clive Taylor, M.D. and Peisheng Hu, M.D. (collectively, the “CTL Parties”), providing for a settlement and release of all claims with respect to our previously disclosed litigation with the CTL Parties. The dismissal of claims was filed in the Superior Court of the State of California for the County of Orange on June 18, 2009. Medibiotech Co., Inc. (“Medibiotech”) and Shanghai Medipharm Biotech Co., Ltd. were once parties to the litigation but previously settled with us.
Under the Settlement Agreement, we agreed to dismiss with prejudice our claims for breach of contract and interference with contractual relations, as well as all other causes of action, stemming from our 1995 license agreement, as amended, with CTL. CTL agreed to dismiss its breach of contract counterclaim, as well as all other causes of action. In connection with the Settlement Agreement, (1) the Company agreed to pay to CTL the sum of four hundred thousand dollars ($400,000) in eight equal monthly installments of fifty thousand dollars ($50,000) commencing upon execution of the Settlement Agreement and continuing on the first business day of each succeeding month until paid in full, (2) CTL agreed to cause to be issued to the Company 950,000 shares of Medibiotech (which represents fifty percent (50%) of the shares of Medibiotech owned by CTL), and (3) the Company and Dr. Epstein entered into a license agreement, effective as of September 20, 1995, pursuant to which Dr. Epstein granted to the Company (i) a fully paid-up, royalty free, exclusive worldwide license to the murine clone TNT1 and (ii) a fully paid-up, royalty free, non-exclusive worldwide (except in the Peoples Republic of China) license to the murine clones TNT2 and TNT3. The foregoing license grants include our right to grant sublicenses, to make, have made, modify, have modified, use, sell and offer for sale, murine clone TNT1, TNT2 and TNT3 products and derivatives thereof, but not to sell the murine clones. We also granted back to Dr. Epstein a limited, fully paid-up, royalty free, exclusive license to the murine clone TNT1, with the right to grant sublicenses, to make, have made, modify, have modified, offer to sell, sell and use the murine clone TNT1 and its products solely in the Peoples Republic of China effective as of August 29, 2001. In consideration for the foregoing license grants, we paid Dr. Epstein the sum of one thousand dollars ($1,000), which amount was deducted from the initial $50,000 payment.
The Settlement Agreement contains a full general release between the Company and the CTL Parties of all action or actions, causes of action, in law or in equity, suits, debts, liens, contracts agreements, promises, liability, claims, demands, damages, loss, cost or expense, of any nature whatsoever, known or unknown, fixed or contingent, by reason of any act, omission, cause, matter or thing whatsoever from the beginning of time.
Information contained herein shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PEREGRINE PHARMACEUTICALS, INC.
Date: June 19, 2009
By:
/s/ Paul J. Lytle
Paul J. Lytle
Chief Financial Officer
-------------------------------------------------------------------
I took this post from Terry D ( Silicon Investor ) .
Medipharm seems to be doing Okay. Looks like LYM-1 (AKA Oncolym) is still a go for Medipharm. They also have the TNT fusion protein technology licensed from USC. I wonder just how much of the TNT technology Peregrine still controls or if we get any royalties from the part Medipharm has.
Shanghai MediPharm Biotech is a wholly-owned subsidiary of Medipharm Biotech Biopharmaceutical Ltd (Bermuda) focused on becoming China’s leading oncology biopharma by providing novel, antibody-based, targeted radio immunotherapy for malig-nant cancers. Following 15 years of R&D in antibody related biopharmaceuticals, the company has a strong intellectual prop-erty portfolio, including Vivatuxin®, a chimeric tumor necrosis therapy approved by China’s State Food and Drug Administra-tion for lung cancer and launched in 2007, as well as other can-didates in radio immunotherapy. Through a strategic marketing collaboration study with the Ministry of Health of China currently covering 101 hospitals, the company has agreements to supply 20,000 doses of Vivatuxin®, priced at $3,000 each, used for the treatment of advanced lung cancer patients, who have previ-ously failed at least one course of chemotherapy, and is negotating collaboration with additional 50 hospitals. Furthermore, as the first radio immunotherapy for solid tumors in the world and a potential therapy for all malignant solid tumors,
Vivatuxin® is undergoing Phase III clinical study registrations for glioma and liver cancer, as well as preclinical trials for colorectal and breast cancers.
Finally, the company has two exclusive licenses in radio immunotherapy technology platforms from University of Southern California Cancer Therapeutic Lab, namely Lym-1 for non-Hodgkin lymphoma, which started Phase I clinical trials in 2010, and TNT fusion protein technology for solid tumors. Currently, MediPharm has a staff of 53 professionals, and with 105,000 square feet GMP-approved world class manufacturing facilities, which include a 500L B. Braun bioreactor, the company has the capacity to produce 100,000 drug doses per year.
http://www.wallstreetresearch.org/
--------------------------------------------------------------
SiliconInvestor
Advanced Search [ sign in ]
register
An important announcement for Silicon Investor members and an introduction from Craig Longhurst
Biotech / Medical : Peregrine Pharmaceuticals, Inc.( PPHM)
Public Reply | Prvt Reply | Mark as Last Read | File Previous 10 | Next 10 | Previous | Next
To: Terry D. who started this subject 1/18/2004 5:25:22 PM
From: cjgaddy of 3711
CHINA TNT Refresher: Interim Lung Results 6-2002
6-19-2002: “INNOVATIVE ADMINISTRATION OF RADIOLABELED TNT SUCCESSFULLY TREATS INOPERABLE LUNG CANCER
TNT Data Presented at Society of Nuclear Medicine’s 49th Annual Meeting”
http://www.peregrineinc.com/prelease.asp?id=6190271436
June 19, 2002 - Peregrine Pharmaceuticals Inc. announced today detailed results from clinical research conducted in China that show 56% efficacy was achieved when patients with inoperable lung cancer were treated with the company's 131iodine labeled chimeric TNT (131I-chTNT) antibody drug using an innovative method of intratumoral injection. Patients treated by this method had a disease control rate of 100%, demonstrating 131I-chTNT can achieve significant therapeutic effects in late stage lung cancer. The results provide substantial validation of Peregrine's proprietary TNT technology, which is a radiolabeled monoclonal antibody that targets the necrotic core of solid tumors. The interim lung cancer data were presented at the Society of Nuclear Medicine's 49th Annual Meeting in Los Angeles. The study was independently designed and conducted by researchers at the Shanghai Tumor Hospital.
The Phase I/II study compared the efficacy of three different methods of administration of 131I-chTNT for patients with inoperable late stage lung cancer: intravenous, intratumoral, and a combination of intravenous plus intratumoral injection. The results demonstrated that the method of intratumoral injection alone achieved a 56% complete and partial tumor remission rate. The combined intravenous plus intratumoral injection method achieved 40% and the intravenous method alone achieved 9% tumor remission rate. The disease control rate for all three methods of treatment, including complete and partial remission and stable disease, was 88% for the 43 patients assessed in the study. The highest therapeutic effect was obtained by using common bronchoscopy and computer tomography (CT) scan instruments in a new technique to directly infuse the tumor with lethal doses of 131I-chTNT.
"Peregrine is reviewing the intratumoral injection techniques used to maximize delivery of radiolabeled TNT to the tumor while minimizing healthy tissue exposure. This will assist us in designing a lung cancer study in the USA," said Edward Legere, CEO of Peregrine Pharmaceuticals. "By using standardized equipment that is routinely used at medical centers around the world, it is possible the treatment could be widely adopted by oncologists treating late stage lung cancer patients."
"This data highlights the promise of TNT for the treatment of late stage lung cancer," said Alan L. Epstein, M.D., Ph.D., co-author of the lung cancer research, inventor of the TNT technology, and Peregrine's scientific consultant. "In this study, intratumoral injection caused substantially higher complete and partial remission rates than the other methods of administration. Given there are no effective treatments for inoperable late stage lung cancer, there is a significant unmet need for new therapies. Directly infusing the drug into the tumor mass may also reduce the systemic toxicity often seen with intravenous administration of radionuclides."
With a population of approximately 1.3 billion, China is a vast market for cancer therapy. Cancer became the main cause of death in China in 1996, with over 7.3 million new cases and just over 3 million deaths annually from cancer in China. The explosion in the number of cases of lung, breast, colon and rectal cancer was caused partly by the aging of China's population. In the USA, there were approximately 170,000 new cases of lung cancer in 1999, making it the most common cancer in the Western world. According to the American Cancer Society and the World Health Organization, since the mid-1990s, about 150,000 Americans have died each year from the disease. Lung cancer is the leading category of cancer death in men, and - since the late 1980s - it has surpassed breast cancer as the leading category of cancer death in women.
Summary of Clinical Study for Lung Cancer:
The poster summarizing the unaudited results of this Phase I/II study can be accessed on Peregrine's web site at:
http://www.peregrineinc.com/Technology.asp?id=Posters+and+Abstracts
As previously announced, a total of 43 patients enrolled in this study had a cytological and histological confirmed diagnosis of stage IIIb (30/43) or IV (13/43) inoperable lung cancer. As confirmed by fine needle biopsy, 24 patients (56%) had a diagnosis of adenocarcinoma, 12 patients (28%) were diagnosed with squamous carcinoma, six patients (14%) with small-cell lung cancer, and one patient (2%) with adeno-squamous carcinoma.
22 patients in the first group were administrated 131I-chTNT by intravenous drug infusion, 16 patients in the second group were administrated by intratumoral injection, and five patients in the third group received both treatments. The dose for each patient was 0.8 mCi/kg, which was repeated two weeks later. Patients receiving intravenous administration were given a total dose of 131I-chTNT delivered in 250 ml of normal saline through a free-flowing intravenous line. For the second group, the intratumoral injection of TNT was directed by thoracic CT guided catheter using a multiple-hole needle. The CT images clearly showed tumor localization, the needle pathway, and the site of administration. In the third group, 75% dosage was given by intratumoral injections and 25% by intravenous infusion.
Partial remission (PR) was defined as a greater than 50% reduction in tumor mass in all lesions and complete remission (CR) as no detectable tumor for greater than 10 weeks. Patients receiving intravenous injection alone had two PR (9%), 16 had stable disease (73%), and four progressed (18%). Those receiving intratumoral injection had one CR (6%), 8 PR (50%), seven had stable disease (44%), and zero progressed. Finally, those in the third group had one CR (20%), one PR (20%), two had stable disease (40%), and one progressed (20%). Toxicity was limited to mild and reversible bone marrow suppression in 20 cases.
Anyone know how the randomization process works overall and for each individual entering a trial site vis a vis our phase 3 trial ?
ON THE SHELF 7
freethemice
Friday, April 06, 2012 11:54:22 AM
Re: cjgaddy post# 78288
Post # of 226979
Here is the poster for AACR 2012 abstract # 1536 on NHS-IL12.
This is the intro and a picture of the structure of the immunocytokine.
Here is the complete poster in jpeg format. You can zoom in to read it.
http://investorshub.advfn.com/uimage/uploads/2012/4/6/drmkzAACR_2012_NHS-IL12_poster.jpg
Thanks to the lead author, Dr. Fallon, at NCI for sending this to me.
It would be very interesting to test this with bavituximab. I think chemo followed by bavituximab, followed by
NHS-IL12 after a short delay. That way the chemo + bavi can attack the tumor first, producing some
necrotic regions, and then the NHS-IL12 can deliver the IL12 to stimulate more immune response to clean up.
In the poster it shows that they tried cyclophosphamide with NHS-IL12 and it improved the response.
ON THE SHELF 6
AACR 2007 (Apr14-18) – 10 PPHM-related Posters
“More than 17,000 scientists from all over the world will gather under the AACR’s banner in what has become the field’s most important intl. annual cancer research meeting.”
http://www.aacr.org/home/scientists/meetings--workshops/annual-meeting-2007/program-in-progress.aspx - click “ONLINE PROCEEDINGS”
1. #3273 (Apr16) ‘Vascular Targeting Antibody Improves Chemotherapy of Prostate Cancer’
Yi Yin, Xianming Huang, Jin He, Troy A. Luster, Philip E. Thorpe - UTSW-MC/Dallas
”Treatment with the combination [2aG4+Docetaxel] reduced the growth of small LNCaP & PC3 tumors by 80-82% and of well-established LNCaP & PC3 tumors by 92-94%. The antitumor effect of the combination treatment was significantly superior to that of the individual treatments (P < 0.01). The combination therapy was no more toxic to the mice than was docetaxel alone as judged by physical signs and body weight changes… The present results provide the foundation for using bavituximab plus docetaxel to treat prostate cancer patients.”
FULL ABSTRACT: http://www.investorshub.com/boards/read_msg.asp?message_id=17860805
2. #4089 (Apr17) ‘Fusion Proteins Composed of Mouse Igg2a Fc and Mouse Beta-2-Glycoprotein 1 Bind to Endothelial Cells with Exposed Phosphatidylserine’ [‘BETABODIES’]
Troy A. Luster, Philip E. Thorpe - UTSW-MC/Dallas
”Recently we determined that 3G4 recognizes PS through the formation of a complex with plasma protein beta-2-glycoprotein 1 (B2GP1)… 3G4 enhances the avidity of B2GP1 for membrane surfaces with exposed PS through the formation of multivalent 3G4/B2GP1/PS complexes. This increased avidity of B2GP1 for PS is likely responsible for targeting of 3G4 to tumor EC with exposed PS… We report here the construction of recombinant fusion proteins composed of mouse IgG2a Fc and mouse b2GP1… These Fc-B2GP1 compounds [‘BETABODIES’] have potential as tumor therapeutic or imaging agents.”
FULL ABSTRACT: http://www.investorshub.com/boards/read_msg.asp?message_id=17860821
3. #4091 (Apr17) ‘Enhancing the Immunogenicity of Glioma Cells with Anti-Phosphatidylserine Antibody’
Jin He, Troy A. Luster, Philip E. Thorpe - UTSW-MC/Dallas
”Rats having orthotopic glioblastomas were treated with single fractionated radiation combined with 2aG4, a mouse monoclonal antibody against PS. The treatment resulted in a marked prolongation of survival time and some tumor cures (15%). Surviving animals were immune to intracerebral challenge with live, untreated F98 cells. These findings suggested that PS on tumor cells might be suppressing host immune response to the tumor cells and that blocking PS with 2aG4 restored immunogenicity… Anti-PS antibody treatment might be combined with radiosurgery in clinical settings to treat brain tumor patients.”
FULL ABSTRACT: http://www.investorshub.com/boards/read_msg.asp?message_id=17860816
4. #3539 (Apr17) ‘Inhibition of Tumor Growth by Targeting Cytokines to the Inside-Out Phosphatidylserine (PS) on Tumor Vascular Endothelium with 2ag4’
Xianming Huang, Dan Ye, Philip Thorpe - UTSW-MC/Dallas
”In this study, immunocytokines between 2aG4, a tumor vascular targeting antibody specific to PS on tumor vascular endothelium, and murine type I interferons or interleukin 2 were developed. The resulting fusion proteins demonstrated both antigen binding and cytokine activities in vitro. The fusion protein was capable of targeting tumor blood vessels and displayed potent anticancer effects in various murine tumor models in vivo without causing any observable toxicity. Especially, the combination of 2aG4-IL-2 with 2aG4-IFNa was significantly better than either single agent alone… These studies demonstrate that 2aG4 immunocytokines could have great potential for targeted immunotherapy of solid tumors.”
FULL ABSTRACT: http://www.investorshub.com/boards/read_msg.asp?message_id=17860809
5. #2128 (Apr16) ‘Blockade of Tumor-Derived VEGF Activation Of VEGF Receptor 2 Reduces Macrophage Infiltration into Tumors and Decreases Metastasis in a Pre-Clinical Orthotopic Model of Pancreatic Cancer’ [HUMAN 2C3]
Juliet G. Carbon, Shane E. Holloway, Andrew F. Miller, Anita Kavlie, Kyle Schlunegger, Jason B. Fleming, Rolf A. Brekken. UTSW-MC/Dallas, Affitech AS, Oslo, Norway, Peregrine Pharm., UT-MDA/Houston
”VEGF binds and activates VEGF receptors 1 and 2 (VEGFR1 & VEGFR2), which are expressed on endothelial and other cell types. Most of the current anti-angiogenic strategies in clinical trials against pancreatic cancer block the activity of both receptors. We have developed 2C3, a mouse monoclonal (mAb) that selectively inhibits VEGF from binding and activating VEGFR2 but not VEGFR1… To bring 2C3 to the clinic, we have developed fully human IgG constructs (Hu2C3) with the same specificity as 2C3. We have found that Hu2C3 reduces the growth, vascularization, and macrophage infiltration of subcutaneous A673 tumors xeongrafts in mice… We have demonstrated that VEGF-VEGFR2 binding is critical for VEGF-induced infiltration of host macrophages into tumors, and selective blockade of this interaction is an attractive therapeutic strategy against pancreatic cancer.”
FULL ABSTRACT: http://www.investorshub.com/boards/read_msg.asp?message_id=17860841
6. #4095 (Apr17) ‘Selective Targeting Of Cellular Immune Responses by Chimeric and Humanized Monoclonal Antibodies To Phosphatidylserine Exposed in Tumor Vasculature’
Monica Friedrich, Amy Brideau-Andersen, Bruce Freimark, Connie Chang - Peregrine Pharm.
”In this study, we evaluate the ability of the chimeric and humanized antibodies to exert anti-tumor effects through various mechanisms, including ADCC, on cellular targets expressing PS… These data demonstrate that humanized 3G4 has comparable target recognition and effector function to bavituximab and, therefore, could be used to treat human cancer patients.”
FULL ABSTRACT: http://www.investorshub.com/boards/read_msg.asp?message_id=17860825
7. #4190 (Apr17) ‘Vasopermeation Enhancement Agents [VEAs]: A Case Study In Screening For The Most Potent Variant In A New Class Of Compounds By Using A Novel Avian Embryonic System’ (Minisymposium)
Kelly A. Felton, John D. Lewis, Andries Zijlstra, Jennifer Chase, Keith A. Luhrs, Aparna I. Roy, Debra A. Harris, Christian Frosch, Steven W. King, Missag H. Parseghian - Peregrine Pharm., London Regional Cancer Program, London, ON, Canada, Vanderbilt Univ., Nashville, TN, Innovascreen, Halifax, NS, Canada, Biobroker, Hamburg, Germany
”Vasopermeation Enhancement Agents (VEAs) are a new class of biologics that are designed to increase the uptake of cancer therapeutics at the tumor site, resulting in a greater efficacy of the compounds, without increasing dosages given to the patient… The lead vasoactive compound under investigation is Interleukin-2 (IL-2) or fragments of that protein… Sensitive quantitative measurements obtained in our novel in vivo assay have allowed us to determine the efficacy of these 11 vasoactive compounds, and this has allowed us to choose the most promising candidates for further pre-clinical studies in mice and monkeys. We believe this is the 1st report of an avian embryonic system being utilized for the commercial evaluation of clinical drug candidates prior to more costly investigations in traditional animal models.”
FULL ABSTRACT: http://www.investorshub.com/boards/read_msg.asp?message_id=17860854
8. #4092 (Apr17) ‘Targeting Truncated Tissue Factor with Tumor Vasculature Specific Monoclonal Antibodies: Developing Coaguligands as Cancer Therapeutics’ [tTF+VTAmabs]
Richard H. Archer, Mary Wakabayashi, Roy Sevilla, Scott Summers, Steven King, Ronald T. Aimes - Peregrine Pharm.
”We have been developing a series of agents that specifically target the established vasculature of solid tumors. Coaguligands, one class of these VTAs, target a truncated form of the procoagulant tissue factor to tumor blood vessels. Truncated tissue factor (tTF) has very weak ability to induce blood coagulation by itself, but becomes a powerful thrombogen for tumor blood vessels when targeted by monoclonal antibodies to tumor vasculature. The coaguligand specifically induces coagulation of tumor vasculature, leading to tumor infarction. We have developed 3 coaguligands (PGN-502, PGN-503, and PGN-504) that link truncated tissue factor to vascular targeting mabs.”
FULL ABSTRACT: http://www.investorshub.com/boards/read_msg.asp?message_id=17860847
***THESE 2 SEEMINGLY INVOLVE DR. MICHAEL ROSENBLUM’S (MDA/TARGA) WORK WITH PPHM’S VTA FUSION TOXIN VEGF121/rGel (sublic. by SUPG from PPHM in 2001)…
…Status a/o 11-2006: "Targa plans to begin mfg. this compound before the end of 2006 in prep. for Ph.1 trials at M.D.Anderson”
…see http://tinyurl.com/ylevod & http://www.targatherapeutics.com/vegfshortsummary.html
9. #4093 (Apr17) ‘The Vascular Ablative Agent VEGF121/rGel Targets Osteoblast Proliferation and Inhibits Prostate Cancer-Induced Bone Formation’ - Khalid A. Mohamedali, Zhi Gang Li, Sehoon Kim, Nora Navone, Michael G. Rosenblum. UT MDA Cancer Center, Houston.
”Our results suggest that VEGF121/rGel may have a therapeutic effect against prostate cancer-mediated osteoblastic lesions in bone.”
10. #5481 (Apr18) ‘Multi-Modality Molecular Imaging of Glioblastoma Growth Inhibition Using the Vascular-Targeting Fusion Toxin VEGF121/rGel’ - Andrew R. Hsu, Weibo Cai, Anand Veeravagu, Kai Chen, Khalid A. Mohamedali, Hannes Vogel, Lewis C. Hou, Victor C.K. Tse, Michael G. Rosenblum, Xiaoyuan Chen. Stanford Univ. School of Medicine, Stanford, CA, UT MDA Cancer Ctr., Houston.
”The results of this study clearly suggest that future clinical multi-modality imaging and therapy using VEGF121/rGel…”
THIS ONE BY DR. ALAN EPSTEIN – UNCERTAIN IF THIS WORK IS RELATED TO PPHM:
#2743 (Apr16) ‘Immune Signatures Reveal Tumor Escape Targets In Mice And Man’ - Rebecca E. Sadun, Suzanne M. Sachsman, William Z. Morris, Xiaoying Chen, Alan L. Epstein - Keck-USC School of Medicine
”groups of tumor-bearing mice were treated with an immunotherapy regimen, LEC/chTNT-3 + PC61, known to produce significant tumor regression in a tumor model-dependent fashion.”
***INTERESTING UNIV-IOWA AACR 2007 POSTER ON THE ROLE OF PS IN THE TUMOR ENVIRONMENT:
#213 (Apr15) ‘Neuroblastoma Express Phosphatidlyserine: Mechanism for Immune Evasion’
Kara Doffek, Xiaocia Yan, Sonia L. Sugg, Bryon Johnson, Joel Shilyansky. Medical College of Wisconsin, Milwaukee, WI, Univ. of Iowa
ABSTRACT:
Introduction: We examined the effect of phosphatidylserine (PS) on tumor immunity. PS is a membrane phospholipid that is restricted to the inner surface of plasma membrane in living cells, but flips to the cell surface during apoptosis. PS may be also expressed on the surface of live tumor cells. PS was reported to promote tolerance, possibly by inhibiting antigen presentation and inflammation. The effect of tumor PS on the immune response against neuroblastoma (NB), a childhood malignancy, was examined in a murine model.
Methods: PS on NB cell surface was determined using Annexin-V (AnV) binding and flow cytometry. To block PS in vivo, NB cells were engineered to secrete AnV protein covalently fused to FLAG, which specifically binds and blocks PS. Western blot was used to determine AnV expression. A/J mice were injected with 104 NB cells subcutaneously and tumor growth was determined.
Results: NB cells were transfected with pre-pro-trypsin AnV-FLAG construct. Western blot analysis was used to quantify AnV production in supernatants and identify NB clones that secreted AnV (AnV-NB). Clones that proliferated in vitro at the same rate as wild type (wt) NB cells were selected. Supernatants from AnV-NB cells blocked PS on the surface of wt NB cells preventing staining with FITC-conjugated recombinant AnV. The findings suggest that secreted AnV blocked PS. The wt and AnV-NB cells were then injected subcutaneously into A/J mice. Tumor homogenates showed continuous AnV expression in vivo. In immunocompetent mice, wt tumors grew faster than AnV-NB cells. In mice depleted of T cells with anti-Thy1.2, no difference in growth rate between wt and AnV-NB tumors was noted. Mice were then immunized two times, 7 days apart, with AnV-NB or control cells. 7 days later mice were injected subcutaneously with 105 wt NB cells. Immunization with An-NB, but not control cells, protected mice from wt NB challenge.
Conclusions: The study demonstrated that mouse NB cells express PS on the cell surface. Blocking PS in vivo by engineering NB cells to secrete AnV slowed tumor growth in immunocompetent but not T cell depleted mice. Importantly, immunization with AnV-NB cells was protective. The findings suggest that PS inhibited anti-tumor T cell immunity in mice. The mechanism of PS action may be indirect inhibition of anti-tumor CTL responses, or activation of regulatory T cells. The studies support the hypothesis that PS expression is a potential mechanism for tumor immune evasion.
ON THE SHELF 5
Wang Yu Bing doctor's personal website wyb95117.haodf.com
Wang Yu Bing physician lecturer
Favorite.
Southern Medical University, Chinese and Western Medicine Hospital of Thoracic Surgery
..
Verified site has all the content published by my doctor Wang Yu Bing
Wang Yu Bing doctor Information Center page
Home
Patient service area
Telephone counseling
Article
Friends suffering
Gifts
.
--------------------------------------------------------------------------------
Location: Good doctor online > Wang Yu Bing doctor Website> Article List > Article Detail
Medical science
On the world's first lung cancer radioimmunotherapy drugs - beautiful green Vivatuxin
Poster: Wang Yu Bing 1197 people have visited
January 14, 2007, the world's first lung cancer radioimmunotherapy DRUG beautiful green (iodine [131I] tumor cell nucleus chimeric monoclonal antibody injection) Listing will be held in Beijing China World Hotel, Science and Technology, the Ministry of Health, the State Food Drug Administration related to leadership, the Asian Clinical Cancer Society (ACOS), Chinese Anti-Cancer Association of Clinical Cancer Studies Collaborative Professional Committee (CSCO) and the person in charge of the country more than 100 clinical cancer specialists participated will be listed. Lung cancer is the world's first killer, the world's new cases each year 1.2 million people, one person every 30 seconds die from lung cancer . In China, lung cancer incidence and mortality is also the highest cancer, cancer prevention is the most important task. For a long time, surgery, radiation therapy, although the control tumors have a good effect in terms of local lesions, but the prevention of tumor recurrence and metastasis has become powerless. Because lung cancer incidence of occult, once found often have lost the chance of operation and chemotherapy and therefore become an important tool, but chemotherapy harmful to human health, in lung cancer patients with advanced often due to inability to tolerate the pain of chemotherapy and give up treatment. With the rise of the monoclonal antibody technology, the radiolabeled monoclonal antibody has been used clinically, it has opened up new ways of treating cancer - radioimmunotherapy (radioimmunotherapy, RIT). Radiolabeled anti -tumor antibodies, injected into the body, the antibody with the corresponding tumor antigen, so as to lock the radioisotope in the tumor site, the radioactivity of the radioisotope continuous, eventually leading to tumor cell necrosis. Radioimmunotherapy is called "biological missile", which combines a monoclonal antibody targeting and killing effects of the strong internal radionuclides, with good efficacy, low side effects features. Currently, only two radioimmunotherapy drugs, the United States Biogen-IDEC's 90Y-ibritumomab (Zevalin) and Britain's GlaxoSmithKline 131I-tositumomab (Bexxar), and by the US FDA approved for lymphoma treatment. Zevalin and Bexxar is radionuclide labeled CD20 monoclonal antibody. Zevalin and Bexxar has been widely applied in Europe for lymphoma treatment provides a powerful weapon. We have reason to believe that in the near future, RIT will become cancer radiotherapy and chemotherapy, cancer molecular therapy and radiation therapy the perfect combination of new targeted therapies. Although RIT in lymphoma achieved such a significant effect of the treatment, but it is for the efficacy of solid tumors has been unsatisfactory. Mainly due to solid tumors sensitive to radiation is not that big. Meanwhile, in the conventional RIT is usually using membrane antigen monoclonal antibody. This led to a series of questions. First, the specific membrane antigen is not at all the tumor cell expression. In other words, the same lung cancer , there are many pathological types, different pathological type of tumor antigen markers vary. Even the same histological type, since the tumor cells expressing the heterogeneity of antigens will be different. And bound antibody also often because of degradation and the inner membrane antigen endocytosis, detached from the binding sites. For these reasons will cause the tumor site radiation dose relative lack of or antibodies to tumor lack of specific targeting, resulting in treatment failure. It is in this context, TNT ( tumor necrosis therapy) antibody emerged. Although TNT antibody development process is full of hardships and setbacks, but ultimately successful RIT overcome the problem in the treatment of solid tumors. Treatment of lung cancer new drug - aesthetic Health (131 tumor cell nuclei chimeric monoclonal antibody injection), is the Shanghai Biological Technology Co., mayne using US patented technology, after 12 years of successful research and development of radioimmunotherapy drugs. Many hospitals in the country nearly eight years of clinical studies indicate that aesthetic Health failed chemotherapy for advanced lung cancer patients have a significant effect, can also be checked after aesthetic injectable birth by radionuclide scanning, so that doctors can easily see if the drug accurate reach the tumor site, to further determine the therapeutic effect. 131I-chTNT (aesthetic Health) by the Chinese SFDA approved for chemotherapy failed for advanced lung cancer treatment. Beautiful listed for the majority of students failed first-line treatment of advanced lung cancer provides a new hope of life of patients. It is the main developer of aesthetic born American L.Epstein University of Southern California School of Medicine professor Alan presentation, TNT antibody locks only tissue degeneration and necrosis of solid tumors, 131I-chTNT and tumor cell nuclear antigen binding, in combination with monoclonal chTNT of radionuclides necrosis edge of tumor killing living cells, resulting in new necrosis, followed by expansion into new monoclonal chTNT necrosis, again and again so that tumor necrosis expanding from the inside out to destroy the tumor , for therapeutic purposes. Currently advanced lung cancer treatment are only 10% efficient, 5-year survival rate of less than 1%, most patients can not get effective treatment. It is reported that, 131I-chTNT treatment of lung cancer Phase II clinical trial in advanced lung cancer patients received 131I-chTNT injection, intravenous injection or injection route of tumor injection, the total effective rate was 34.6%. The trial proved that 131I-chTNT treatment of lung cancer is effective, but its side effects are also tolerated. Aesthetic born in China market, bringing a new treatment for the Chinese people lung choice, the majority of advanced lung cancer patients hope.
Share to
Posted: 2011-10-08 14:49
I want to call the doctor and Wang Yu Bing Wang Yu ice I want to consult a doctor
.
Review
No comment, I'll post the first to review!
Comment
???????...
.
Related articles
Molecular targeted cancer therapy.
Surgical treatment of lung cancer.
Different stages of lung cancer treatment.
Treatment of lung cancer drugs - beautiful green Vivatuxin.
Radiation therapy for lung cancer.
Progress in lung cancer radiotherapy.
Lung cancer (NSCLC) Advances in Radiotherapy.
Radiation therapy for lung cancer.
Lung Cancer Radiotherapy.
Related consulting
Radiation particles by radiofrequency ablation of lung cancer treatment.
Lung new drug treatment.
Is there a new drug to treat lung cancer and Japanese cooperation?.
Radiation particles by radiofrequency ablation of lung cancer treatment.
Useful in your hospital gamma knife radiation treatment of lung cancer.
Will my body multiple bone metastasis of lung cancer father with radionuclide therapy for it.
81-year-old lung cancer patient, I ask whether the hospital can do radiation therapy for lung cancer?.
My mother 80 years old last year found that the hilar lung cancer, is now the right upper lung metastasis, whether radiotherapy.
Will tumor immunotherapy mean? Clinical trials mean?.
Radiation therapy and combined therapy in patients with lung cancer can prolong life?.
Dr. Wang Yu Bing information
Testimonials: 17 Gifts: 21
Love: Contribution Value: 15036
Department:
Southern Medical University, Chinese and Western Medicine Hospital of Thoracic Surgery
Wang Yu Bing doctor telephone advice
Dr. Wang Yu Bing has launched telephone service
directly to the doctor I call convenient! Quick!
Recent calls:
2015-07-09 18:23 Shaanxi h *** whole esophagus caused by boiling water to burn
2015-06-26 20:09 Guangdong h *** accident patients faint spot
2013-06-23 11:08 Liaoning h *** 2001 year due to error
2012-10-28 12:04 Guangdong *** from a memory I have come to
2012-10-16 21:59 Hunan h *** Vet Hello!
2012-06-16 15:05 Guangxi h *** Case: 2 patients
..
ON THE SHELF 4
purpledawgs
Saturday, 01/17/15 05:06:02 AM
Re: entdoc post# 203054
Post # of 226971
Entdoc
I posted this a little over a week ago and had no response. Is this PPHM's or not? Recent - October 2014
"Speaking of our china subsidiary:
Is this our TNT antibody? I can't remember what rights we obtained out of the lawsuit.
Cell Biochem Biophys. 2014 Oct 8. [Epub ahead of print]
Effectiveness of Combined 131I-chTNT and Radiofrequency Ablation Therapy in Treating Advanced Hepatocellular Carcinoma.
Tu J1, Ji J, Wu F, Wang Y, Zhang D, Zhao Z, Ying X.
Author information
Abstract
To investigate the effectiveness of monoclonal antibody (131I-chTNT) and radiofrequency ablation (RFA) combination therapy in treating middle-advanced stage hepatocellular carcinoma (HCC). Thirty-four patients diagnosed with HCC patients, divided into two groups comprised of 22 and 12 cases were included in this retrospective study. The two groups received RFA with or without (131I-chTNT) therapy, respectively. The patients in these groups were followed up for a median of 31 and 35 months, respectively. Patient survival was evaluated using Kaplan-Meier method and safety profiles were determined by analyzing liver, thyroid, and bone marrow toxicities. This retrospective study showed that survival time of the patients who received combination therapy was significantly longer than that of the RFA group (P = 0.052). The median progress-free survival of patients in the two groups was 23 and 7 months, respectively, and the difference was significant (P = 0.04). Tumor recurred in 3.5-8.7 months in four of the combination group patients, among which three had newly developed lesions. The red blood cells and platelets counts were not altered on day 7 and 1 month of the treatment, however, number of white blood cells was significantly increased on day 7 which was reversed back to the normal range in 2 weeks. The ALT and AST were also not significantly altered on day 7 and 1 month of therapy. In middle-advanced stage HCC patients, the combination of 131I-chTNT and RFA therapy was found to be significantly more effective than the RFA treatment alone as assessed in short-term follow-up. However, the dose we used was insufficient to completely block the local recurrence of the lesions with a diameter of 5 cm or larger.
PMID: 25293788 [PubMed - as supplied by publisher] "
Thanks,
ON THE SHELF 3
TECHNICLONE ISSUED PATENT ON VASOPERMEATION ENHANCEMENT.
Feb, 2000
Biotech Business
Techniclone Corporation (NASDAQ:TCLN), Tustin, Calif., has announced that the U.S. Patent Office has granted a US Patent No. 6007817 for Techniclone's Vasopermeation Enhancement Agent ("VEA") technology. The VEA technology is one of Techniclone's platform technologies, which will be used to enhance drug uptake in solid tumors. This broad patent covers the use of the VEA agents for the treatment of all solid tumors in conjunction with chemotherapeutic agents, monoclonal antibodies, cytokines and other therapeutic agents.
The technology was developed to be administered prior to the administration of most existing cancer therapies. Preclinical studies in animal models have shown that drug uptake can be increased up to 400% in specific instances by using the VEA technology as a pretreatment.
http://www.entrepreneur.com/tradejournals/article/58674378.html
iHub NewsWire
--------------------------------------------------------------------------------
DBMM Looks to Acquisition to Grow Digital Clarity Brand(DBMMD) Jul 20, 2015 12:40 PM North American Cannabis Holdings Announces NaturesComfortMeds JV In Conjunction With Aug 3rd Spin-off And Shareholder Dividend(USMJ) Jul 20, 2015 9:33 AM SourcingLink.net; Eldor Property Phase 1 Exploration Announcement(SNET) Jul 20, 2015 8:30 AM Fresh Healthy Vending and American Diabetes Association Partner to Promote Corporate Initiative "Wellness Lives Here"(VEND) Jul 20, 2015 8:12 AM QUASAR ANNOUNCES MANAGEMENT CHANGE(QASP) Jul 17, 2015 1:00 PM
Around the Web
--------------------------------------------------------------------------------
Public Reply | Private Reply | Keep | Last Read
Post New Msg
Replies (1) | Next 10 | Previous | Next
Follow Board
Follow User
Ignore User
Keyboard Shortcuts
Report TOS Violation
© 2015 InvestorsHub.Com, Inc.
About
Investor Relations (OTC:IHUBY)
About Us
Terms of Service
Privacy Policy
Advertise With Us
Investor Relations
Data Accreditations
Disclaimer
Help
FAQ
Site Map
Handbook
Q&A Forum
Contact Us
Tutorials
Educational
Educational Channel
Stock Market 101
Educational Videos
Investor Help Forum
More
iHub on Facebook
iHub on Twitter
iHub iPhone/iPad App
iHub Android App
iHub BlackBerry App
StockWiki
Auditorium
iHub NewsWire
You are 2ndstr2thert on WEB3
ON THE SHELF 2
For those who do not know PPHM owns shares in a Chinese company
that is and has been treating patients in China with one of our TNT products ( VIVATUXIN - TNT 3 AND I131 )and LYM 1.
Anyone have any idea how much these shares are currently worth in USA dollars ?
Peregrine Pharmaceuticals, Inc. (the “Company”) entered into a Settlement Agreement and Mutual General Release dated June 4, 2009 (the “Settlement Agreement”) with Cancer Therapeutics Laboratories (“CTL”), Alan Epstein, M.D. (“Dr. Epstein”), Clive Taylor, M.D. and Peisheng Hu, M.D. (collectively, the “CTL Parties”), providing for a settlement and release of all claims with respect to our previously disclosed litigation with the CTL Parties. The dismissal of claims was filed in the Superior Court of the State of California for the County of Orange on June 18, 2009. Medibiotech Co., Inc. (“Medibiotech”) and Shanghai Medipharm Biotech Co., Ltd. were once parties to the litigation but previously settled with us.
Under the Settlement Agreement, we agreed to dismiss with prejudice our claims for breach of contract and interference with contractual relations, as well as all other causes of action, stemming from our 1995 license agreement, as amended, with CTL. CTL agreed to dismiss its breach of contract counterclaim, as well as all other causes of action. In connection with the Settlement Agreement, (1) the Company agreed to pay to CTL the sum of four hundred thousand dollars ($400,000) in eight equal monthly installments of fifty thousand dollars ($50,000) commencing upon execution of the Settlement Agreement and continuing on the first business day of each succeeding month until paid in full, (2) CTL agreed to cause to be issued to the Company 950,000 shares of Medibiotech (which represents fifty percent (50%) of the shares of Medibiotech owned by CTL), and (3) the Company and Dr. Epstein entered into a license agreement, effective as of September 20, 1995, pursuant to which Dr. Epstein granted to the Company (i) a fully paid-up, royalty free, exclusive worldwide license to the murine clone TNT1 and (ii) a fully paid-up, royalty free, non-exclusive worldwide (except in the Peoples Republic of China) license to the murine clones TNT2 and TNT3. The foregoing license grants include our right to grant sublicenses, to make, have made, modify, have modified, use, sell and offer for sale, murine clone TNT1, TNT2 and TNT3 products and derivatives thereof, but not to sell the murine clones. We also granted back to Dr. Epstein a limited, fully paid-up, royalty free, exclusive license to the murine clone TNT1, with the right to grant sublicenses, to make, have made, modify, have modified, offer to sell, sell and use the murine clone TNT1 and its products solely in the Peoples Republic of China effective as of August 29, 2001. In consideration for the foregoing license grants, we paid Dr. Epstein the sum of one thousand dollars ($1,000), which amount was deducted from the initial $50,000 payment.
The Settlement Agreement contains a full general release between the Company and the CTL Parties of all action or actions, causes of action, in law or in equity, suits, debts, liens, contracts agreements, promises, liability, claims, demands, damages, loss, cost or expense, of any nature whatsoever, known or unknown, fixed or contingent, by reason of any act, omission, cause, matter or thing whatsoever from the beginning of time.
Information contained herein shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PEREGRINE PHARMACEUTICALS, INC.
Date: June 19, 2009
By:
/s/ Paul J. Lytle
Paul J. Lytle
Chief Financial Officer
-------------------------------------------------------------------
I took this post from Terry D ( Silicon Investor ) .
Medipharm seems to be doing Okay. Looks like LYM-1 (AKA Oncolym) is still a go for Medipharm. They also have the TNT fusion protein technology licensed from USC. I wonder just how much of the TNT technology Peregrine still controls or if we get any royalties from the part Medipharm has.
Shanghai MediPharm Biotech is a wholly-owned subsidiary of Medipharm Biotech Biopharmaceutical Ltd (Bermuda) focused on becoming China’s leading oncology biopharma by providing novel, antibody-based, targeted radio immunotherapy for malig-nant cancers. Following 15 years of R&D in antibody related biopharmaceuticals, the company has a strong intellectual prop-erty portfolio, including Vivatuxin®, a chimeric tumor necrosis therapy approved by China’s State Food and Drug Administra-tion for lung cancer and launched in 2007, as well as other can-didates in radio immunotherapy. Through a strategic marketing collaboration study with the Ministry of Health of China currently covering 101 hospitals, the company has agreements to supply 20,000 doses of Vivatuxin®, priced at $3,000 each, used for the treatment of advanced lung cancer patients, who have previ-ously failed at least one course of chemotherapy, and is negotating collaboration with additional 50 hospitals. Furthermore, as the first radio immunotherapy for solid tumors in the world and a potential therapy for all malignant solid tumors,
Vivatuxin® is undergoing Phase III clinical study registrations for glioma and liver cancer, as well as preclinical trials for colorectal and breast cancers.
Finally, the company has two exclusive licenses in radio immunotherapy technology platforms from University of Southern California Cancer Therapeutic Lab, namely Lym-1 for non-Hodgkin lymphoma, which started Phase I clinical trials in 2010, and TNT fusion protein technology for solid tumors. Currently, MediPharm has a staff of 53 professionals, and with 105,000 square feet GMP-approved world class manufacturing facilities, which include a 500L B. Braun bioreactor, the company has the capacity to produce 100,000 drug doses per year.
http://www.wallstreetresearch.org/
--------------------------------------------------------------
SiliconInvestor
Advanced Search [ sign in ]
register
An important announcement for Silicon Investor members and an introduction from Craig Longhurst
Biotech / Medical : Peregrine Pharmaceuticals, Inc.( PPHM)
Public Reply | Prvt Reply | Mark as Last Read | File Previous 10 | Next 10 | Previous | Next
To: Terry D. who started this subject 1/18/2004 5:25:22 PM
From: cjgaddy of 3711
CHINA TNT Refresher: Interim Lung Results 6-2002
6-19-2002: “INNOVATIVE ADMINISTRATION OF RADIOLABELED TNT SUCCESSFULLY TREATS INOPERABLE LUNG CANCER
TNT Data Presented at Society of Nuclear Medicine’s 49th Annual Meeting”
http://www.peregrineinc.com/prelease.asp?id=6190271436
June 19, 2002 - Peregrine Pharmaceuticals Inc. announced today detailed results from clinical research conducted in China that show 56% efficacy was achieved when patients with inoperable lung cancer were treated with the company's 131iodine labeled chimeric TNT (131I-chTNT) antibody drug using an innovative method of intratumoral injection. Patients treated by this method had a disease control rate of 100%, demonstrating 131I-chTNT can achieve significant therapeutic effects in late stage lung cancer. The results provide substantial validation of Peregrine's proprietary TNT technology, which is a radiolabeled monoclonal antibody that targets the necrotic core of solid tumors. The interim lung cancer data were presented at the Society of Nuclear Medicine's 49th Annual Meeting in Los Angeles. The study was independently designed and conducted by researchers at the Shanghai Tumor Hospital.
The Phase I/II study compared the efficacy of three different methods of administration of 131I-chTNT for patients with inoperable late stage lung cancer: intravenous, intratumoral, and a combination of intravenous plus intratumoral injection. The results demonstrated that the method of intratumoral injection alone achieved a 56% complete and partial tumor remission rate. The combined intravenous plus intratumoral injection method achieved 40% and the intravenous method alone achieved 9% tumor remission rate. The disease control rate for all three methods of treatment, including complete and partial remission and stable disease, was 88% for the 43 patients assessed in the study. The highest therapeutic effect was obtained by using common bronchoscopy and computer tomography (CT) scan instruments in a new technique to directly infuse the tumor with lethal doses of 131I-chTNT.
"Peregrine is reviewing the intratumoral injection techniques used to maximize delivery of radiolabeled TNT to the tumor while minimizing healthy tissue exposure. This will assist us in designing a lung cancer study in the USA," said Edward Legere, CEO of Peregrine Pharmaceuticals. "By using standardized equipment that is routinely used at medical centers around the world, it is possible the treatment could be widely adopted by oncologists treating late stage lung cancer patients."
"This data highlights the promise of TNT for the treatment of late stage lung cancer," said Alan L. Epstein, M.D., Ph.D., co-author of the lung cancer research, inventor of the TNT technology, and Peregrine's scientific consultant. "In this study, intratumoral injection caused substantially higher complete and partial remission rates than the other methods of administration. Given there are no effective treatments for inoperable late stage lung cancer, there is a significant unmet need for new therapies. Directly infusing the drug into the tumor mass may also reduce the systemic toxicity often seen with intravenous administration of radionuclides."
With a population of approximately 1.3 billion, China is a vast market for cancer therapy. Cancer became the main cause of death in China in 1996, with over 7.3 million new cases and just over 3 million deaths annually from cancer in China. The explosion in the number of cases of lung, breast, colon and rectal cancer was caused partly by the aging of China's population. In the USA, there were approximately 170,000 new cases of lung cancer in 1999, making it the most common cancer in the Western world. According to the American Cancer Society and the World Health Organization, since the mid-1990s, about 150,000 Americans have died each year from the disease. Lung cancer is the leading category of cancer death in men, and - since the late 1980s - it has surpassed breast cancer as the leading category of cancer death in women.
Summary of Clinical Study for Lung Cancer:
The poster summarizing the unaudited results of this Phase I/II study can be accessed on Peregrine's web site at:
http://www.peregrineinc.com/Technology.asp?id=Posters+and+Abstracts
As previously announced, a total of 43 patients enrolled in this study had a cytological and histological confirmed diagnosis of stage IIIb (30/43) or IV (13/43) inoperable lung cancer. As confirmed by fine needle biopsy, 24 patients (56%) had a diagnosis of adenocarcinoma, 12 patients (28%) were diagnosed with squamous carcinoma, six patients (14%) with small-cell lung cancer, and one patient (2%) with adeno-squamous carcinoma.
22 patients in the first group were administrated 131I-chTNT by intravenous drug infusion, 16 patients in the second group were administrated by intratumoral injection, and five patients in the third group received both treatments. The dose for each patient was 0.8 mCi/kg, which was repeated two weeks later. Patients receiving intravenous administration were given a total dose of 131I-chTNT delivered in 250 ml of normal saline through a free-flowing intravenous line. For the second group, the intratumoral injection of TNT was directed by thoracic CT guided catheter using a multiple-hole needle. The CT images clearly showed tumor localization, the needle pathway, and the site of administration. In the third group, 75% dosage was given by intratumoral injections and 25% by intravenous infusion.
Partial remission (PR) was defined as a greater than 50% reduction in tumor mass in all lesions and complete remission (CR) as no detectable tumor for greater than 10 weeks. Patients receiving intravenous injection alone had two PR (9%), 16 had stable disease (73%), and four progressed (18%). Those receiving intratumoral injection had one CR (6%), 8 PR (50%), seven had stable disease (44%), and zero progressed. Finally, those in the third group had one CR (20%), one PR (20%), two had stable disease (40%), and one progressed (20%). Toxicity was limited to mild and reversible bone marrow suppression in 20 cases.
ON THE SHELF 1
COTARA-( I131 CH T.N.T.1/B ) is the fusion of a
radioactive particle-( iodine 131 ) and a monoclonal
antibody-( T.N.T. ). Radioactive iodine 131 gives off a
lethal burst of gamma rays within a 300 cell radius. The half life of I131 is approximately 8 days and it does not degrade off the antibody for approximately 10 days.
The Tumor Necrosis Targeting agent-( T.N.T. ) is the vehicle that carries iodine 131 to the cancer cells. because it is a chimeric antibody-( part mouse part human )allergic reactions are minimal. T.N.T. homes in on necrotic tissue found in the core of all solid based tumors. Cancer cells have leaky spots that allows
Cotara entrance-(normal cells do not ). Cotara is too large to fit through the outer membrane of a normal cell-( which also has some but relatively small amounts of necrotic tissue at its core ). Cotara is unique in that it is the only therapeutic agent that will attack ANY solid based tumor large enough to have a necrotic core and leave healthy tissue alone. Other monoclonal antibody therapies are geared for particular cancers - Cotara will seek out and deliver its deadly cargo to ALL solid based tumors.
Many monoclonal antibodies rely on finding and latching
on to specific docking sites found on the surface of cancer cells. If the antibody does not " overwhelm " the tumor then the disease is poised for a comeback. If the docking sites are used up and/or cell surface mutations have altered the sites then what at first appeared to be an effective modality will now be relatively useless. In contrast Cotara becomes more effective with each subsequent dose, since after each application more and more necrotic tissue forms thus presenting a larger and larger target.
Because our docking site is at the core of the tumor the problems associated with the lack of cell surface docking sites and/or mutations are eliminated.
Cotara does not merely interfere with cellular machinery. It is a powerful treatment that will incinerate more and more of the tumor from the inside out -( and send those toxic cells back into hell where they belong ).
According to Dr.Patel there has been some swelling associated with Cotara when used in treating a form of brain cancer. The problem was however manageable when steroids were used.
M.A.T.-( MODIFIED ANTIBODIES TECHNOLOGY) I copied this from an old Yahoo post. This is the "B" in
I131 CH T.N.T./B.
by: ownotshort (64/M/Seattle,WA) 07/19/99 01:20 pm
Msg: 27817 of 256647
" Techniclone scientists discovered that when a small organic molecule like the vitamin biotin is attached to a monoclonal antibody it decreases its electrical charge. Decreasing the electrical charge of the antibody dramatically influences the way the antibody travels in the blood stream. The positive electrical charge of an un-modified antibody gives it a sticky characteristic that causes it to stick to capillary walls as it passes through the blood stream. This stickiness causes delayed antibody circulation, decreased tumor uptake and increased antibody clearance time (time it takes the antibody and toxic payload to clear from the blood stream). Increased clearance time results in higher toxicity.
Decreasing the antibody clearance time may dramatically reduce the toxicity of many, if not most, monoclonal antibody/toxic drug therapies. The increase in monoclonal antibody uptake at the tumor site should result in an increase in drug efficacy. Monoclonal antibodies using TCLN s MAT clear from the bloodstream in half of the time of normal antibodies and produce a 2-3-fold increase in antibody/tumor uptake.
0N THE SHELF ?- TNT platform(Cotara,Vivatuxin,Selectine)-2C3-Truncated tissue factor-Oncolymn.
Here is a follow-up to Dumbster's post. I have no idea if patent expirations are in effect,ownership rights have been terminated,or any other legal/science complications are involved with these products. I am bringing all this up to expand the knowlege base of the new investors and to interject some different avenues of thought while we wait for Bavi news.
Much of the potential of the TNT platform has not been fully reseached. If you live in the NYC area you
will see and hear commercials touting the benefits of targeted
radiation therapies (Cyberknife,radioactive seeds,etc.).I find it hard
to believe that the unmatched precision radioactive delivery that
Cotara can provide is a dead end technology . Cotara will "burn up" a
primary tumor as well as its metastases. The TNT antibody can also be
used as an imaging agent.I understand and agree
that bavi without the problems associated with radioactivity-its more
natural immune stimulating approach- and its anti viral potential was
the way to go, but if funds permit sometime in the future the TNT
platform should be explored-it might even be the best type of PS
ellicitor(better than Docetaxel?)and therefore a better complement to Bavi.
The following posts will shed some light as to why many of the old
timers saw something unique about TCLN-PPHM. I'm not a scientist so
anyone feel free to make corrections or update the data.
If JB thought she could make an improvement to the randomization procedures why wouldn't she bring this to light before the trial started rather than placing her career at risk ?
Second time for this post but I did not get any replies. Anyone care to comment ? TIA
CP-Mojojojo are both of you still enthusiastic about the possibility of AA for NSCL as per posts 155972 and 155975 ?
If so would either of you care to SPECULATE ( not holding anyone to any timeframe -just appreciate the knowlege base each of you draw from )when ? TIA.
CP-Mojojojo are both of you still enthusiastic about the possibility of AA for NSCL as per posts 155972 and 155975 ?
If so would either of you care to SPECULATE ( not holding anyone to any timeframe -just appreciate the knowlege base each of you draw from )when ? TIA.
Is there ever a point where management has to disclose a buyout offer ? T.I.A.
One of the problems with the share price is Tustins refusal-inability-legal constrictions ( take your pick )to explain in a LAY FRIENDLY WAY why the FDA APPROVED AND FAST TRACTED the phase 3 NSCL trial. Explain why we believe we have a superior immunostimuilatory drug in Bavituximab. Explain the known facts surrounding the sabotage .
No one is asking for deception . Lord knows no ethical person wants to deceive cancer patients, but for God's sake let the retail investing world know what we have. Just maybe you will garner enough intelligent longs to raise and somewhat stabilize the share price in an upward trend.
We know the risk -reward ratio , Tustin let the rest of the retail world know too - many would accept the risk as per we longs.
PS Chris' article at the very least helped relieve some angst.